NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AG-20-053 from the NIH Guide for Grants and Contracts
Notice NOT-TR-21-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-21-002 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support intervention research aimed at equipping the dental workforce in meeting the unique needs of people living with HIV (PLWH) or at risk of contracting HIV. This initiative aligns with the United States Department of Health and Human Services (DHHS) plan, Ending the HIV Epidemic: A Plan for America, which identifies four broad goals: 1) Diagnose individuals infected with HIV as soon as possible after infection; 2) Treat HIV infection rapidly and effectively to achieve sustained viral suppression; 3) Protect people at risk for HIV using potent and proven prevention strategies, including Pre-exposure Prophylaxis (PrEP); and 4) Respond rapidly to detect growing HIV clusters and to prevent new HIV infections. Dental care providers may have unique opportunities to contribute to these efforts, but there are also significant challenges. Among the most commonly-cited challenges are concerns about patient acceptability, the need for appropriate provider training and support, fitting HIV-related services into the dental clinic workflow, complex and variable laws related to HIV service-provision, and billing and reimbursement systems necessary for sustainability. Applications in response to this FOA should propose to develop, adapt, and/or test interventions to equip dental care providers to participate in and/or to provide HIV-related services, consistent with those identified in the DHHS plan. Proposed interventions should address one or more challenges currently preventing greater participation by dental care providers, and can aim to overcome barriers at any relevant socioecological level (e.g., individual patient or provider, community, clinic, care organization). Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3).
Funding Opportunity PAR-21-093 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity RFA-AG-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure to support the Alzheimer's Disease Sequencing Project (ADSP) and related to data collection, longitudinal follow-up, ascertainment of antecedent risk factors, and the characterization of additional relatives from families multiply affected by Alzheimer's disease and related dementias (AD/ADRD) in order to expand the existing NIA Late Onset of AD Family Based Study sample set.
Notice NOT-OD-21-041 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-008 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-023 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-019 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-022 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-097 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-NNN, the R61/R33 option).
Funding Opportunity PAR-21-098 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-NNN, the R34 option).
Notice NOT-OD-21-040 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-064 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than $500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of $700,000 or more may also be a criteria for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application.
Funding Opportunity PAR-21-063 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-XXX, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.
Funding Opportunity RFA-ES-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When developed and validated, these methodologies or approaches will further advance the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, promote more comprehensive understanding of human exposures, susceptibility and adverse health outcomes.
Funding Opportunity RFA-ES-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.
Notice NOT-LM-21-003 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-HG-21-020 from the NIH Guide for Grants and Contracts